| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10989-015-9503-7 |
| P50 | author | Stefania De Luca | Q32421561 |
| Michele Saviano | Q42602207 | ||
| Enrica Calce | Q46142129 | ||
| P2860 | cites work | Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD | Q24805375 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| How to measure and predict the molar absorption coefficient of a protein | Q27860551 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Calculation of protein extinction coefficients from amino acid sequence data | Q27861073 | ||
| Spectroscopic Determination of Tryptophan and Tyrosine in Proteins* | Q29555850 | ||
| Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review | Q33561966 | ||
| Synthetic multivalent ligands in the exploration of cell-surface interactions | Q34096477 | ||
| Peptide receptor radionuclide therapy | Q34321940 | ||
| Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives | Q34390584 | ||
| Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. | Q34531054 | ||
| Radiolabeled carbohydrated somatostatin analogs: a review of the current status | Q35798410 | ||
| Hitting multiple targets with multimeric ligands | Q35976363 | ||
| The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine | Q37433324 | ||
| Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design | Q38025254 | ||
| HER2-mediated anticancer drug delivery: strategies to prepare targeting ligands highly specific for the receptor | Q38494593 | ||
| (99m)Tc-labeled dimeric octreotide peptide: a radiotracer with high tumor uptake for single-photon emission computed tomography imaging of somatostatin receptor subtype 2-positive tumors | Q39139584 | ||
| First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography | Q40550081 | ||
| Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor | Q41915374 | ||
| Fluorescence study for selecting specific ligands toward HER2 receptor: an example of receptor fragment approach | Q43705433 | ||
| Cysteine co-oxidation process driven by native peptide folding: an example on HER2 receptor model system | Q46142037 | ||
| A SPR strategy for high-throughput ligand screenings based on synthetic peptides mimicking a selected subdomain of the target protein: a proof of concept on HER2 receptor. | Q51563880 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Spanning binding sites on allosteric proteins with polymer-linked ligand dimers | Q59070068 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 237-242 | |
| P577 | publication date | 2015-12-17 | |
| P1433 | published in | International Journal of Peptide Research and Therapeutics | Q15757092 |
| P1476 | title | Development of Targeting Ligands for HER2 Receptor: Simplified Receptor Model Employed for Selecting Highly Specific Molecules | |
| P478 | volume | 22 |
Search more.